Bispecific antibody-drug conjugates (BsADCs) are a promising class of therapeutics that combine the targeting specificity of antibodies with the cytotoxic potency of small molecule drugs. BOC Sciences offers comprehensive services to support the development of BsADCs, including antibody engineering, linkage chemistry, and payload conjugation. With our expertise and state-of-the-art facilities, we can help customers accelerate the development of BsADCs and bring them to market faster.
The development of ADCs and bsAbs has many similarities. In order to appropriately address the safety, effectiveness, and delivery issues of their payloads, an increasing number of studies have combined ADCs and bsAbs to form BsADCs. Studies have shown that BsADC can potentially expand the therapeutic scope of ADC and improve bsAb with higher internalization. Therefore, it helps to reduce the death of non-specific adjacent cells or normal cells, targeting tumor cells with reduced surface proteins as an immune escape or defense mechanism, and reducing the optimal dose.
Fig. 1. Representative ADCs with different conjugation methods (Biomolecules. 2020, 10(3): 360).
BsADC involve a combination of bsAb and ADC. Currently, BsADC candidates in clinical trials target anti-TAA, such as HER2, HER3, EGFR, MUC1 and MET. In addition to target selection, efficient absorption of therapeutics requires easy internalization and lysosomal translocation. For high-load internalization into tumor cells, many transmembrane proteins, including prolactin receptor (PRLR), cytokine receptors, and CD63, can also be used as targets. Studies have shown that anti-HER2/PRLR BsADCs treated with MMAE can complement the limitations of anti-HER2 ADCs. Anti-HER2/CD63 bsADCs containing duostatin-3 induce rapid uptake via CD63 and exhibit strong cytotoxicity against HER2-positive breast and gastric tumors.
Bispecific antibodies are relatively complex, and their efficacy is related to the target combination of the antibody, the structure of the antibody, and the affinity of the two antibodies. ADC is also a complex compound, and its efficacy is related to antibodies, linkers, toxins, etc. Therefore, dual-antibody ADCs will be more complex, and their design requires a deep understanding of the mechanism of action of dual-antibody ADCs and the principles of ADCs. At present, dual-antibody ADCs have just started, and most of them are in the preclinical stage. Judging from the current preclinical data, dual-antibody ADCs have better efficacy than naked antibodies:
The development of BsADC is a complex and challenging process that requires expertise in antibody engineering, linker chemistry, and payload conjugation. BOC Sciences offers a range of development support services that can help our customers overcome these challenges and accelerate BsADC development. Our team of experienced scientists and state-of-the-art facilities ensure that we can provide high-quality services to meet our clients' specific needs. With our support, our customers can benefit from faster development times, lower costs, and a higher chance of clinical success.
Antibody engineering is a critical step in the development of BsADCs. BOC Sciences offers a range of antibody engineering services to support the development of BsADCs, including antibody humanization, affinity maturation and bispecific antibody generation. Our team of experienced scientists and state-of-the-art facilities ensure that we can provide high-quality antibody engineering services to meet our clients' specific needs. With our support, our customers can benefit from improved antibody specificity, reduced immunogenicity, and enhanced therapeutic potential of BsADCs.
Linker chemistry is an important aspect of BsADCs development. BOC Sciences offers a range of linker chemistry services to support the development of BsADCs, including linker design, synthesis and characterization. Our team of experienced chemists and state-of-the-art facilities ensure that we can provide high-quality linker chemistry services to meet our customers' specific needs. With our support, our customers can benefit from improved linker stability, reduced off-target effects, and enhanced therapeutic potential of BsADCs.
Payload conjugation is a critical step in the development of BsADCs. BOC Sciences offers a range of payload conjugation services to support BsADC development, including payload development, conjugation chemistry and ADC characterization. Our team of experienced chemists and state-of-the-art facilities ensure that we can provide high-quality payload conjugation services to meet our customers' specific needs. With our support, our customers can benefit from improved payload stability, reduced off-target effects, and enhanced therapeutic potential of BsADCs.
BOC Sciences' one-stop bispecific ADC service platform services involve the development and production of bispecific antibody drug conjugates (ADCs). The platform leverages advanced technology and expertise to design and engineer bispecific antibodies that can target multiple antigens simultaneously. Our services include:
BOC Sciences has an experienced team of scientists and state-of-the-art facilities to provide high-quality and cost-effective ADC development services. Focused on quality, efficiency and innovation, our ADC services platform is designed to accelerate the development of ADCs and help customers bring novel therapies to market. If you are interested in our ADC development support services, please contact us to discuss the possibility of collaboration.